PHM
52
-2
GPS
50
-2
HRB
65
2
STX
39
-2
EMR
42
-2
BDX
33
-2
MCD
50
-2
NRG
82
5
ORLY
64
4
NDAQ
46
-2
CI
58
-4
EXR
28
-7
EMN
73
-2
KHC
43
3
T
30
-2
HST
53
-4
ETR
57
-3
URI
56
-3
EQT
48
-2
TDC
62
3
PHM
52
-2
GPS
50
-2
HRB
65
2
STX
39
-2
EMR
42
-2
BDX
33
-2
MCD
50
-2
NRG
82
5
ORLY
64
4
NDAQ
46
-2
CI
58
-4
EXR
28
-7
EMN
73
-2
KHC
43
3
T
30
-2
HST
53
-4
ETR
57
-3
URI
56
-3
EQT
48
-2
TDC
62
3
Financhill
Back

Fate Therapeutics 10K Form

Sell
27

FATE
Fate Therapeutics

Last Price:
5.28
Seasonality Move:
6.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q FATE/Fate Therapeutics Quarterly
2023-08-08 10Q FATE/Fate Therapeutics Quarterly
2023-05-03 10Q FATE/Fate Therapeutics Quarterly
2022-11-03 10Q FATE/Fate Therapeutics Quarterly
2022-08-03 10Q FATE/Fate Therapeutics Quarterly
2022-05-04 10Q FATE/Fate Therapeutics Quarterly

Receive FATE News And Ratings

See the #1 stock for the next 7 days that we like better than FATE

FATE Financial Statistics

Sales & Book Value

Annual Sales: $63.53M
Cash Flow: $-36.82M
Price / Cash Flow: 0
Annual Sales: $3.74
Price / Book: 1.42

Profitability

EPS (TTM): -1.64000
Net Income (TTM): $-160.93M
Gross Margin: $0
Return on Equity: -37.07%
Return on Assets: -27.09%

Fate Therapeutics Earnings Forecast

Key Fate Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for FATE is 0.00%.
  • The Selling, General & Administrative Expenses for FATE have been equal to 128.20% of Gross Profit Margin.
  • The Research & Development expenses have been 271.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of FATE is -253.30% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Fate Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FATE
CUSIP: 31189P
Website: fatetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.48
Quick Ratio: 8.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FATE Technical Analysis vs Fundamental Analysis

Sell
27
Fate Therapeutics (FATE) is a Sell

Is Fate Therapeutics a Buy or a Sell?

  • Fate Therapeutics stock is rated a Sell
    The current Fate Therapeutics [FATE] share price is $5.27. The Score for FATE is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.